Purpose: There are only a few studies on characteristics and outcomes of late recurrence (LR) of urothelial carcinoma of bladder (UCB) after radical cystectomy (RC). The objective of this study was to assess characteristics and oncological outcomes of such LR that developed 5 years after RC. Materials and Methods: We retrospectively reviewed 570 patients who underwent RC and bilateral regional lymphadenectomy for UCB at our institution. Comparisons of post-recurrence disease-specific survival (DSS) according to the timing of recurrence and the site of recurrence were performed using Kaplan-Meier survival curves and log-rank test. Cox regression model was fitted to assess factors for post-recurrence DSS. Results: Disease recurrence occurred in 214 (37.5%) patients, including 20 (9.3%) who had LRs. Median time from RC to recurrence was 13.0 (interquartile range 6.0–32.0) months. There were no significant differences in clinicopathological factors between early- and late-recurrence groups. Post-recurrence 5-year DSS was not significantly different (21.6 vs. 14.1%, p = 0.344) between early- and late-recurrence groups. However, it was worse in the nonurothelial recurrence group compared to that in the urothelial recurrence group (14.0 vs. 19.4%, p = 0.056). Older age (HR 1.03, 95% CI 1.01–1.05, p = 0.001), nonorgan-confined disease at RC (HR 1.73, 95% CI 1.15–2.61, p = 0.008), and lymph node invasion (HR 1.58, 95% CI 1.01–2.45, p = 0.043) were significant predictors for post-recurrence 5-year DSS. Conclusions: LR after RC with lymphadenectomy is not common. However, it cannot be overlooked. LR had similar characteristics to early recurrence. Interestingly, the time to recurrence did not affect post-recurrence survival.

Keywords:
Urinary bladder, Carcinoma, Late recurrence, Survival
1.
Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
J Urol
. 2006 Dec;176(6 Pt 1):2414–22; discussion 2422.
2.
Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.
J Clin Oncol
. 2001 Feb;19(3):666–75.
3.
Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, et al. Radical cystectomy for bladder cancer today–a homogeneous series without neoadjuvant therapy.
J Clin Oncol
. 2003 Feb;21(4):690–6.
4.
Mitra AP, Quinn DI, Dorff TB, Skinner EC, Schuckman AK, Miranda G, et al. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy.
BJU Int
. 2012 Mar;109(6):846–54.
5.
Moschini M, Karnes RJ, Sharma V, Gandaglia G, Fossati N, Dell’Oglio P, et al. Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: A 20-year single center experience.
Eur J Surg Oncol
. 2016 May;42(5):735–43.
6.
Sonpavde G, Khan MM, Lerner SP, Svatek RS, Novara G, Karakiewicz PI, et al. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer.
J Urol
. 2011 Feb;185(2):456–61.
7.
Solsona E, Iborra I, Rubio J, Casanova J, Dumont R, Monrós JL. Late oncological occurrences following radical cystectomy in patients with bladder cancer.
Eur Urol
. 2003 May;43(5):489–94.
8.
Soria F, Moschini M, Wirth GJ, Gust KM, Klatte T, Briganti A, et al. Characterization of Late Recurrence After Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients.
Urology
. 2017 Aug;106:119–24.
9.
Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, et al.; Bladder Cancer Research Consortium. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy.
BJU Int
. 2013 Mar;111(3b 3 Pt B):E30–6.
10.
Linder BJ, Boorjian SA, Hudolin T, Cheville JC, Thapa P, Tarrell RF, et al. Late recurrence after radical cystectomy: patterns, risk factors and outcomes.
J Urol
. 2014 May;191(5):1256–61.
11.
Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Eur Urol
. 2017 Mar;71(3):447–61.
12.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.
Ann Surg Oncol
. 2010 Jun;17(6):1471–4.
13.
Eble JN, Sauter G, Epstein JI, Sesterhenn IA.
World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs
. Lyon, France: IARC Press; 2004.
14.
Giannarini G, Kessler TM, Thoeny HC, Nguyen DP, Meissner C, Studer UE. Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution?
Eur Urol
. 2010 Oct;58(4):486–94.
15.
Niegisch G, Nini A, Michalski R, Henn A, Mally D, Albers P, et al. Comparison of 2-Year oncological outcome and early recurrence patterns in patients with urothelial bladder carcinoma treated with open or robot-assisted radical cystectomy with an extracorporeal urinary diversion.
Urol Int
. 2018;101(2):224–31.
16.
Bochner BH, Kattan MW, Vora KC; International Bladder Cancer Nomogram Consortium. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.
J Clin Oncol
. 2006 Aug;24(24):3967–72.
17.
Nuhn P, May M, Sun M, Fritsche HM, Brookman-May S, Buchner A, et al. External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder.
Eur Urol
. 2012 Jan;61(1):58–64.
18.
Moschini M, Shariat SF, Freschi M, Soria F, Abufaraj M, Gandaglia G, et al. Impact of prostate involvement on outcomes in patients treated with radical cystoprostatectomy for bladder cancer.
Urol Int
. 2017;98(3):290–7.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.